Pfizer's 6% Yield: 90% Cash Payout Ratio Keeps Dividend Safe

For income-focused portfolios, a 6% yield and a stock down 50% from its peak usually signal distress. Pfizer's case separates accounting earnings from cash generation: while the earnings payout ratio is above 100%, the cash dividend payout ratio is about 90%, backed by $12.7 billion in cash and short-term investments. That balance sheet cushion is the core of the bull case for dividend sustainability.

Pfizer (NYSE: PFE) has become a litmus test for income investors as its dividend yield hovers around 6% while the stock trades more than 50% below its 2021 high. A September 12, 2026 analysis by The Motley Fool concludes that the payout is likely sustainable in the near term, despite an earnings-based payout ratio that is well north of 100%. The key insight is an accounting one: dividends are funded by cash, not accrual earnings. When judged on cash, Pfizer's dividend consumes roughly 90% of cash flow, which is high but still leaves a modest margin of coverage.

“

Pfizer's case separates accounting earnings from cash generation: while the earnings payout ratio is above 100%, the cash dividend payout ratio is about 90%, backed by $12.7 billion in cash and short-term investments.

Pfizer reported nearly $12.7 billion in cash and short-term investments at the end of the second quarter of 2026. It paid approximately $4.9 billion in dividends during the first half of the year, implying an annualized dividend cost in the neighborhood of $9.8 billion. That means the company's existing cash balance alone could cover more than a full year of shareholder payouts. Management has also been explicit about wanting to maintain the dividend in the near term, which suggests the board is not currently planning a cut.

The divergence between earnings and cash flow is common in capital-intensive industries like pharmaceuticals, where non-cash charges such as amortization of acquired intangibles, impairments, and restructuring costs can depress reported net income even while operating cash flow remains positive. Pfizer faces typical industry headwinds, including patent expirations and pricing pressures, which have contributed to its revenue and earnings decline from pandemic-era peaks. The stock's fall from its 2021 high reflects investor concern that those headwinds will persist.

For income investors, the 6% yield is attractive relative to most fixed income and broad equity yields, but it also embodies risk. A payout ratio above 100% on earnings means the company is paying out more than it earns on a GAAP basis. That is not automatically a red flag if free cash flow covers the dividend, but it means dividend growth is unlikely and any cash flow deterioration could quickly pressure the payout. The 90% cash payout ratio is near the upper end of comfort for a company that also needs cash for research and development, debt service, and potential acquisitions.

Another sign of near-term safety is the absolute size of the cash cushion relative to dividend obligations. With $12.7 billion in cash and short-term investments and roughly $9.8 billion in annual dividends, a full year of distributions could be funded even if cash flow temporarily went to zero. That is an unusually strong position for a company whose earnings payout ratio looks alarming. But the dividend isn't risk-free: maintaining it consumes resources that might otherwise fund late-stage pipeline development, targeted bolt-on acquisitions, or debt reduction.